ScholarIQanswers from OpenAlex

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures

PaperCitations, authors & open-access status

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures have?

ScholarIQcitation count

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures has 221 citations in the OpenAlex counts ScholarIQ stores.

When was Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures published?

ScholarIQyear

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures has 2001 year in the ScholarIQ index.

What is the open-access status of Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures?

ScholarIQoa status

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures has closed oa status in the ScholarIQ index.

What is the DOI of Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures?

ScholarIQdoi

The DOI for Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures is on the source record.

What is the PMID of Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures?

ScholarIQpmid

The PMID for Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures is on the source record.

What is the OpenAlex record for Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures?

ScholarIQopenalex

The OpenAlex for Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial